¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2018-08-25

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2018-08-25
±³À°ÀÏÀÚ : 2018-08-25
±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ¾Ïº´¿ø B1 ´ë°­´ç  
±³À°ÁÖÁ¦ : 2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ      
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574  
À̸ÞÀÏ : app@app2010.com      
±³À°Á¾·ù : ºñ´¢±â°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 30,000¿ø      
ºñ°í »çÀüµî·Ï 3¸¸¿ø, ÇöÀåµî·Ï 4¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 08¿ù 25ÀÏ  08:30~09:00 Registration  () 
±âŸ 08¿ù 25ÀÏ  09:00~09:05 President's Welcome  () 
±âŸ 08¿ù 25ÀÏ  09:05~09:10 Congratulatory Remarks  () 
±³À°½Ã°£ 08¿ù 25ÀÏ  09:10~10:10 Podium Session I: Prostate Cancer  () 
±³À°½Ã°£ 08¿ù 25ÀÏ  10:10~10:30 The Debilitating Impact of Bone Complications in mCRPC  Dr. Alan(So (UBaCn cVouver Prostate Centre, Canada) 
È޽Ġ08¿ù 25ÀÏ  10:30~10:50 Coffee Break  () 
±³À°½Ã°£ 08¿ù 25ÀÏ  10:50~11:05 Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: When and How?  Á¤½ÂÀÏ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  11:05~11:20 Management of Recurrent Nonmuscle Invasive Bladder Cancer after Adequate BCG or Mtomycin  ½É¸í¼±(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  11:20~11:35 Long-term Outcomes after Bladder-preserving Tri-modal Therapy versus Radical Cystectomy for Muscle-invasive Bladder Cancer: Update  ÇÔ¿ø½Ä(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  11:35~11:50 The Role of Neoadjuvant Chemotherapy: Who Will Benefit?  ±¸ÀÚÇö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  11:50~12:20 The Significance of Testosterone and Gonadotropin Suppression in Advanced Prostate Cancer Treatment  Dr. Peter Busch ¨ªstergren(Herlev and Gentofte Hospital, Denmark) 
±âŸ 08¿ù 25ÀÏ  12:20~12:25 Àü¸³¼±¾Ï Áø·á±Ç°í¾È ¹ß°£ ±â³ä½Ä  () 
½Ä»ç 08¿ù 25ÀÏ  12:25~13:20 Lunch (Àüü »çÁø ÃÔ¿µ)  () 
±âŸ 08¿ù 25ÀÏ  13:20~13:40 ¿¬¼öº¸°íȸ  () 
±âŸ 08¿ù 25ÀÏ  13:40~14:00 Project 2017 Report / 2018 Proposal  () 
±³À°½Ã°£ 08¿ù 25ÀÏ  14:00~15:00 Podium Session II: Bladder and Renal Cancer  () 
È޽Ġ08¿ù 25ÀÏ  15:00~15:20 Coffee Break  () 
±³À°½Ã°£ 08¿ù 25ÀÏ  15:20~16:20 Podium Session III: Prostate Cancer  () 
±³À°½Ã°£ 08¿ù 25ÀÏ  16:20~16:35 Genomic Analysis in Prostate Cancer: Where Are We?  °­¹Î¿ë(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  16:35~16:50 Androgen Receptor Variants in Prostate Cancer: Where Are We?  ÇÏÈ«±¸(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  16:50~17:05 Management of Oligometastatic Prostate Cancer from Imaging to Therapy  ±è¸í±â(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 08¿ù 25ÀÏ  17:05~17:20 Androgen Receptor (AR) Targeted Therapy for Non-metastatic Castration-resistant Prostate Cancer (CRPC)  Á¤À翵(±¹¸³¾Ï¼¾ÅÍ) 
±âŸ 08¿ù 25ÀÏ  17:20~17:50 2018 KUOS Annual Business Meeting  () 
±âŸ 08¿ù 25ÀÏ  17:50~18:00   () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2018-08-25""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦13Â÷ ´ëÇѽŰæ¿Ü°úÇÐȸ ¼­¿ï°æÀÎ(°­¿ø-Á¦ÁÖ)Áöȸ : 2018-08-25
´ÙÀ½±Û ´ëÇѽ½°üÀýÇÐȸ Á¦5ȸ Korea-Japan Knee Osteotomy Symposium : 2018-08-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21062 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(4ÀÏÂ÷) : 2024-07-04 0 119 2024-06-18
21061 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀçÅÃÀÇ·á ȯÀÚ Áø·áÀÇ ½ÇÁ¦ : 2024-07-04 0 70 2024-06-18
21060 ¿ï»ê ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ¿ï»êÁöȸ ¿¬¼ö±³À°(¿ù°æÅë, µ¥³ë¼ö¹ä Áß´Ü ÈÄ ¹Ýµ¿°ñÀýÀÇ ¿¹¹æ) : 2024-07-04 0 98 2024-06-18
21059 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(3ÀÏÂ÷) : 2024-07-03 0 19 2024-06-18
21058 °æ±â 2024³â ÆòÅýÃÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-02 0 109 2024-06-18
21057 ¼­¿ï ¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(2ÀÏÂ÷) : 2024-07-02 0 83 2024-06-18
21056 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 64 2024-06-18
21055 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(1ÀÏÂ÷) : 2024-07-01 0 52 2024-06-18
21054 ÃæºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Understanding Current Community Mental Health and Emotional Disorders in ASD : 2024-07-01 0 93 2024-06-18
21053 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 59 2024-06-18
21052 °æ±â ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦2ȸ CHAMS °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 63 2024-06-18
21051 ¼­¿ï 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ Çϰ迬¼ö°­Á : 2024-06-30 0 78 2024-06-18
21050 ºÎ»ê 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-30 0 35 2024-06-18
21049 ¼­¿ï Á¦26Â÷ ´ëÇѾƵ¿º´¿øÇùȸ Ãá°èÇмú´ëȸ : 2024-06-30 0 26 2024-06-18
21048 Ãæ³² 2024 ÀÌ°úÇÐ ¿¬±¸¼¼¹Ì³ª : 2024-06-29 0 27 2024-06-18
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷